PD-L1 expression on tumor cells and tumor-associated immune cells (combined positive score [CPS]) showed better efficacy than PD-L1 expression on tumor cells of immune checkpoint inhibitors in the treatment of advanced GC/GEJC/esophageal adenocarcinoma (9). Here, CD274 is linked to esophageal adenocarcinoma.